blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - multipelt myelom - antineoplastiska medel - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
galantamin sandoz 16 mg depotkapsel, hård
sandoz a/s - galantaminhydrobromid - depotkapsel, hård - 16 mg - galantaminhydrobromid 20,504 mg aktiv substans - galantamin
galantamin sandoz 24 mg depotkapsel, hård
sandoz a/s - galantaminhydrobromid - depotkapsel, hård - 24 mg - galantaminhydrobromid 30,756 mg aktiv substans - galantamin
galantamin sandoz 8 mg depotkapsel, hård
sandoz a/s - galantaminhydrobromid - depotkapsel, hård - 8 mg - galantaminhydrobromid 10,252 mg aktiv substans - galantamin
galantamin actavis 16 mg depotkapsel, hård
actavis group ptc ehf. - galantaminhydrobromid - depotkapsel, hård - 16 mg - galantaminhydrobromid 20,504 mg aktiv substans - galantamin
galantamin stada 16 mg depotkapsel, hård
stada arzneimittel ag - galantaminhydrobromid - depotkapsel, hård - 16 mg - galantaminhydrobromid 20,504 mg aktiv substans - galantamin
galantamin orion 16 mg depotkapsel, hård
orion corporation - galantaminhydrobromid - depotkapsel, hård - 16 mg - galantaminhydrobromid 20,504 mg aktiv substans - galantamin
galantamin 2care4 16 mg depotkapsel, hård
2care4 aps - galantaminhydrobromid - depotkapsel, hård - 16 mg - galantaminhydrobromid 20,5 mg aktiv substans; natriumlaurilsulfat hjälpämne - galantamin
galantamin actavis 24 mg depotkapsel, hård
actavis group ptc ehf. - galantaminhydrobromid - depotkapsel, hård - 24 mg - galantaminhydrobromid 30,756 mg aktiv substans - galantamin
galantamin stada 24 mg depotkapsel, hård
stada arzneimittel ag - galantaminhydrobromid - depotkapsel, hård - 24 mg - galantaminhydrobromid 30,756 mg aktiv substans - galantamin